UNSPSC 51434804: Cronidipine

This classification denotes a calcium channel blocker with the molecular formula C30H32ClN3O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TXJ9MY5V9, chemically known as (8-(p-chlorophenyl)-1,4-dioxa-8-azaspiro(4,5)dec-2-yl)methyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as cronidipine, which bears US NIH Compound Identifier 65918. European Medicines Agency schedules Cronidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06826MIG.

UNSPSC 51434804 Cronidipine, a Commodity code, represents prescription pharmaceuticals and related medication products that state and local governments procure for emergency medical services, health system formularies, and pharmacy benefit programs. State and local buyers under this code include city fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state government jurisdictions. The scope of work encompasses supply of branded and generic medications meeting FDA requirements, expiration-dating standards, and safety compliance with OSHA Hazard Communication Standards, often bundled with distribution logistics, cold-chain management where required, and product replacement for expired stock before contractual shelf-life limits are reached. Issuing bodies typically structure procurements as firm-price sealed bids or RFPs with one-year initial terms and renewal options, occasionally incorporating small local business enterprise set-asides or bid discounts.

Recent activity shows geographic spread across Florida, Texas, and multi-state cooperative purchasing regions. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue with a due date of April 8, 2026 and estimated contract value of $40,000.00, incorporating a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local government facilities in Minnesota and Oregon, with contract awards effective July 1, 2026, weighted 75 percent on price competitiveness and requiring 3 percent administrative fees on all purchases.